Targovax Announces Interim Results From Phase I Trial of ONCOS-102 in Checkpoint Inhibitor Refractory Melanoma

One of the first six patients showed a complete response to the treatment OSLO, Norway, Sept. 27, 2018 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, today announces interim tumor...

from PR Newswire: //https://ift.tt/2xHMNDJ